AbbVie achieves win for migraine prevention drug Aquipta in Europe
The decision brings the first daily oral migraine prophylactic to Europe, with plans to rollout the treatment as soon as possible.
The decision brings the first daily oral migraine prophylactic to Europe, with plans to rollout the treatment as soon as possible.
What's Your Reaction?
